Expertise in
11
conditions

Michelle A. Farrar

High Street, 
Randwick, NSW, AU 
Expertise in
11
conditions
High Street, 
Randwick, NSW, AU 

Overview

Michelle Farrar practices practicing medicine in Randwick, Australia.

Ms. Farrar is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Muscle Atrophy, and Spinal Muscular Atrophy Type 2.

She is actively involved in clinical research, co-authoring 170 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

High Street, Randwick, NSW 2031, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

170 Total Publications

Eligibility for Thrombolysis for Pediatric Acute Ischemic Stroke.
Eligibility for Thrombolysis for Pediatric Acute Ischemic Stroke.
Journal: Stroke
Published: August 27, 2026

Frequently Asked Questions about Michelle A. Farrar

Is Michelle A. Farrar a top-rated expert for Spinal Muscular Atrophy (SMA)?

MediFind is an objective health platform that identifies experts based on real-world data. Michelle A. Farrar is classified as an Elite expert for Spinal Muscular Atrophy (SMA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michelle A. Farrar participate in research or clinical trials?

Yes. Michelle A. Farrar has published 170 articles and abstracts on conditions like Spinal Muscular Atrophy (SMA). You can view a list of Michelle A. Farrar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Farrar's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile